Skip to main content

Clinical Trials Using Pegylated Liposomal Doxorubicin Hydrochloride

Review the clinical trials studying pegylated liposomal doxorubicin hydrochloride on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-22 of 22

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Status: Active
Location: 21 locations
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
Status: Active
Location: 20 locations
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Status: Active
Location: 18 locations
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination with an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
Status: Active
Location: 16 locations
Avelumab with Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients with Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
Status: Active
Location: 13 locations
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Active
Location: 8 locations
Second-Line Pembrolizumab in Combination with Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma
Status: Active
Location: 8 locations
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Status: Active
Location: 7 locations
CDX-301 and CDX-1140 Immunotherapy in Combination with Pegylated Liposomal Doxorubicin Chemotherapy for the Treatment of Stage III and IV HER2 Negative Breast Cancer
Status: Active
Location: 7 locations
A Study of ZN-c3 in Patients With Ovarian Cancer
Status: Active
Location: 8 locations
Ibrutinib, Temozolomide, Etoposide, Pegylated Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Rituximab in Treating Patients with Primary Central Nervous System Lymphoma
Status: Active
Location: 3 locations
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
Status: Active
Location: 2 locations
ALX148 in Combination with Liposomal Doxorubicin and Pembrolizumab for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Botensilimab, Balstilimab, and Liposomal Doxorubicin in Combination with Ultrasound-Mediated Blood Brain Barrier Opening for the Treatment of Patients with Newly Diagnosed Glioblastoma
Status: Active
Location: Northwestern University, Chicago, Illinois
Durvalumab in Combination with Chemotherapy in Treating Patients with Advanced Solid Tumors, DURVA+ Trial
Status: Active
Location: National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients with Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
Disulfiram, Copper Gluconate, and Liposomal Doxorubicin for the Treatment of Patients with Relapsed or Refractory Sarcomas
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Combination Chemotherapy and Bevacizumab with the NovoTTF-100L/ NovoTTF-200T System in Treating Patients with Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Paclitaxel or Liposomal Doxorubicin for HIV-positive Persons with Kaposi Sarcoma
Status: Approved
Location: Location information is not yet available.
Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients with Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer
Status: Approved
Location: Roswell Park Cancer Institute, Buffalo, New York
A Cancer Vaccine (STEMVAC) in Combination with Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer
Status: Approved
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Immunotherapy (Pembrolizumab) and Chemotherapy (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) with ctDNA-Guided Consolidation for the Treatment of Relapsed or Refractory Classic Hodgkin Lymphoma
Status: Approved
Location: University of California San Francisco, San Francisco, California